Technical Analysis for SABS - SAB Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | -1.94% | |
| Earnings Movers | Other | -1.94% | |
| Wide Bands | Range Expansion | -1.94% | |
| Gapped Up | Strength | -1.94% | |
| 20 DMA Resistance | Bearish | 4.11% | |
| NR7 | Range Contraction | 4.11% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 7 hours ago |
| 10 DMA Support | about 7 hours ago |
| Down 5% | about 8 hours ago |
| Down 3% | about 8 hours ago |
| Fell Below Previous Day's Low | about 8 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/28/2024
SAB Biotherapeutics, Inc. Description
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Pharmaceutical Immunology Immune System Immunotherapy Diabetes Infectious Diseases Autoimmune Disease Antibodies Antibody Immunotherapies Influenza Genetic Engineering Us Government Human Diseases Transplantation Glycoproteins Polyclonal Antibodies Type 1 Diabetes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.5 |
| 52 Week Low | 2.36 |
| Average Volume | 18,868 |
| 200-Day Moving Average | 5.83 |
| 50-Day Moving Average | 3.42 |
| 20-Day Moving Average | 2.97 |
| 10-Day Moving Average | 2.92 |
| Average True Range | 0.31 |
| RSI (14) | 48.45 |
| ADX | 24.44 |
| +DI | 15.96 |
| -DI | 21.11 |
| Chandelier Exit (Long, 3 ATRs) | 2.57 |
| Chandelier Exit (Short, 3 ATRs) | 3.40 |
| Upper Bollinger Bands | 3.44 |
| Lower Bollinger Band | 2.51 |
| Percent B (%b) | 0.57 |
| BandWidth | 31.29 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.15 |
| MACD Histogram | 0.0458 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.38 | ||||
| Resistance 3 (R3) | 3.35 | 3.20 | 3.32 | ||
| Resistance 2 (R2) | 3.20 | 3.11 | 3.22 | 3.30 | |
| Resistance 1 (R1) | 3.12 | 3.06 | 3.16 | 3.15 | 3.28 |
| Pivot Point | 2.98 | 2.98 | 3.00 | 2.99 | 2.98 |
| Support 1 (S1) | 2.89 | 2.89 | 2.94 | 2.93 | 2.80 |
| Support 2 (S2) | 2.75 | 2.84 | 2.77 | 2.78 | |
| Support 3 (S3) | 2.67 | 2.75 | 2.76 | ||
| Support 4 (S4) | 2.70 |
